Clinical management of cutaneous adverse events in patients with chemotherapy
Sanmartín O, Beato C, Suh-Oh HJ, Aragón I, España A, Majem M, et al. Manejo clínico de los eventos adversos […]
See more ▸
Trastuzumab emtansine in patients with MBC HER2+
Manso, L., Sanchez-Muñoz, A., Calvo, I., et al. 2018 Late Administration of Trastuzumab Emtansine Might Lead to Loss of Chance […]
See more ▸
Predictive biomarker testing in colorectal carcinoma
García-Alfonso, P., García-Carbonero, R., García-Foncillas, J. et al. Update of the recommendations for the determination of biomarkers in colorectal carcinoma: […]
See more ▸
Evaluation of circulating tumour markers in breast cancer
Ayala de la Peña, F., Ortiz-Muñoz, B., Quintanar-Verdúguez, T. et al. Consensus of the Spanish society of laboratory medicine and […]
See more ▸
Optimising the detection of NTRK gene alterations
Garrido, P., Hladun, R., de Álava, E. et al. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in […]
See more ▸
Clinical management of patients with stage III NSCLC
Majem, M., Hernández-Hernández, J., Hernando-Trancho, F. et al. Multidisciplinary consensus statement on the clinical management of patients with stage III […]
See more ▸
Predictive biomarker testing in advanced NSCLC
Garrido, P., Conde, E., de Castro, J. et al. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: […]
See more ▸
Cancer management during pregnancy
Cubillo, A., Morales, S., Goñi, E. et al. Multidisciplinary consensus on cancer management during pregnancy. Clin Transl Oncol (2020). https://doi.org/10.1007/s12094-020-02491-8 […]
See more ▸
Secondary thromboprophylaxis in patients with cancer
Quintanar, T., Font, C., Gallardo, E. et al. Consensus statement of the Spanish Society of Internal Medicine and the Spanish […]
See more ▸
Liquid biopsy in oncology
Remon, J., García-Campelo, R., de Álava, E. et al. Liquid biopsy in oncology: a consensus statement of the Spanish Society […]
See more ▸
One third of the drugs approved by the FDA and the EMA have a high therapeutic value
In a retrospective analysis recently published in the British Medical Journal, it was observed that a third of the drugs […]
See more ▸
FDA accept ‘Priority Review’ for lurbinectedin in small-cell lung cancer
PharmaMar and Jazz Pharmaceuticals have just announced that the American regulatory agency FDA has accepted the Priority Review of lurbinectedin […]
See more ▸